TFOS Recognizes the Bioprotectant Properties of Trehalose, a Component of Thealoz Duo, in the Treatment of Dry Eye
The TFOS international Dry Eye WorkShop II (TFOS DEWS II), whose report has been published in the July 2017 issue of the Ocular Surface journal, acknowledged that trehalose is an effective ingredient in association with hyaluronic acid for the treatment of dry eye.
Thealoz Duo (trehalose 3%, hyaluronic acid 0.15%), developed by Laboratoires Théa, is registered as a medical device and is indicated to relieve dry eye disease symptoms. Thealoz Duo has a unique mode of action, related to the association of its two active ingredients: sodium hyaluronate (hyaluronic acid) and trehalose. Hyaluronic acid has been long known for its hydration and lubrication properties. Trehalose is a natural bioprotectant and osmoprotectant, found in numerous plants and animals, to allow cell survival in unfavorable environments. The TFOS DEWS II report specifically showcases that in vitro and in vivo studies have shown that trehalose:
- protects corneal cells from desiccation,
- protects corneal and conjunctival cells from apoptosis,
- protects corneal cells from ultraviolet-induced oxidative damage by accelerating corneal healing,
- reduces the number of conjunctival inflammatory cytokines,
- helps to restore osmotic balance to the ocular surface, to prevent denaturation of cell membrane lipid bilayers and proteins,
- prevents denaturation of cell membrane lipid bilayers and proteins and maintains the homeostasis of corneal cells.[5]
According to Professor Benitez del Castillo (Spanish Society of ophthalmology and Ocular Surface Specialist), “the association of hyaluronic acid and trehalose can be considered a significant progress in the treatment of moderate to severe dry eye syndrome, acting at the same time on dry eye disease and its clinical symptoms.”
The TFOS DEWS II report is a massive undertaking involving 150 clinical and basic research experts from around the world. They used an evidence-based approach and a process of open communication, dialogue and transparency to achieve a global consensus regarding multiple aspects of dry eye disease.